Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
Sanofi, Regeneron reports positive Phase 2 study of dupilumab in patients with CSwNP

Sanofi, Regeneron reports positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. [More]
GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]
Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

A multidisciplinary team of experts affiliated with the Cedars-Sinai Movement Disorders Program will present a free conference for patients, families and caregivers on treatment options for dystonia, which causes painful and potentially crippling muscle contractions. [More]
Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment. [More]
Cancer specialist outlines 10 symptoms that should never be ignored

Cancer specialist outlines 10 symptoms that should never be ignored

Patients often ask, "Doc, is this something to worry about?" Patients fear the worst yet often choose to ignore potentially deadly warning signs. [More]
Alectinib promise for crizotinib-resistant NSCLC

Alectinib promise for crizotinib-resistant NSCLC

Alectinib has shown promising antitumour activity in patients with ALK-rearranged non-small-cell lung cancer that is resistant to crizotinib, researchers report. [More]
Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204). [More]
Pneumonia in COPD patients has distinct clinical features

Pneumonia in COPD patients has distinct clinical features

The aetiology and clinical features of community-acquired pneumonia are different in people with chronic obstructive pulmonary disease than in those without the lung condition, Spanish research demonstrates. [More]
Migraine in middle age linked to Parkinson's disease

Migraine in middle age linked to Parkinson's disease

A paper recently published in American Academy of Neurology suggests that migraine in middle age may indicate an increased risk of developing a movement disorder, such as Parkinson’s disease. The study also showed that people who experienced migraine with aura were twice as likely to develop Parkinson’s disease compared with those who did not suffer from headaches. [More]
Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. [More]
New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma. [More]
FDA approves use of Menactra for booster vaccination against meningococcal disease

FDA approves use of Menactra for booster vaccination against meningococcal disease

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age. [More]
Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects. [More]
Clinical studies to treat unmet medical need post-transplantation

Clinical studies to treat unmet medical need post-transplantation

A class of biotechnology drugs called monoclonal antibodies is now being tested in clinical studies to treat an unmet medical need post-transplantation, called delayed graft function [More]
Study suggests that energy drinks can cause heart problems

Study suggests that energy drinks can cause heart problems

Energy drinks can cause heart problems according to research presented at ESC Congress 2014 today by Professor Milou-Daniel Drici from France. [More]
Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets now available in U.S. for people with diabetes

Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. [More]
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]